THE NHS is failing to keep up with science, experts blasted after breakthrough new dementia drugs were rejected again by the ...

With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's ...

New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

Last week, it was announced that two new “breakthrough” treatments for Alzheimer’s had been turned down for NHS use. The tone ...

Discover breaking news detailing why the NHS will not cover two new Alzheimer’s drugs due to the high annual costs.

The National Institute for Health and Care Excellence (NICE) has today issued final decisions on lecanemab and donanemab, ...

A groundbreaking analysis from leading British universities has uncovered surprising links between everyday medications and ...

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. They represent a huge step forward in research because they target a known cause of the disease, ...